References in Guidelines

1. Cleary PA, Orchard TJ, Genuth S, et al.; DCCT/
EDIC Research Group. The effect of intensive
glycemic treatment on coronary artery calcification
in type 1 diabetic participants of the Diabetes
Control and Complications Trial/Epidemiology of
Diabetes Interventions and Complications (DCCT/
EDIC) Study. Diabetes 2006;55:3556–3565

2. Nathan DM, Cleary PA, Backlund JYC,
et al.; Diabetes Control and Complications
Trial/Epidemiology of Diabetes Interventions and
Complications (DCCT/EDIC) Study Research Group.
Intensive diabetes treatment and cardiovascular
disease in patients with type 1 diabetes. N Engl J
Med 2005;353:2643–2653

3. Diabetes Control and Complications Trial
(DCCT)/Epidemiology of Diabetes Interventions
and Complications (EDIC) Study Research Group.
Mortality in type 1 diabetes in the DCCT/EDIC
versus the general population. Diabetes Care
2016;39:1378–1383

4. Writing Team for the Diabetes Control and
Complications Trial/Epidemiology of Diabetes
Interventions and Complications Research Group.
Effect of intensive therapy on the microvascular
complications of type 1 diabetes mellitus. JAMA
2002;287:2563–2569

5. Holt RIG, DeVries JH, Hess-Fischl A, et al. The
management of type 1 diabetes in adults. A
consensus report by the American Diabetes
Association (ADA) and the European Association
for the Study of Diabetes (EASD). Diabetes Care
2021;44:2589–2625

6. Tricco AC, Ashoor HM, Antony J, et al. Safety,
effectiveness, and cost effectiveness of long
acting versus intermediate acting insulin for
patients with type 1 diabetes: systematic review
and network meta-analysis. BMJ 2014;349:g5459

7. Bartley PC, Bogoev M, Larsen J, Philotheou A.
Long-term efficacy and safety of insulin detemir
compared to neutral protamine Hagedorn insulin
in patients with type 1 diabetes using a treatto-
target basal-bolus regimen with insulin aspart
at meals: a 2-year, randomized, controlled trial.
DiabetMed 2008;25:442–449

8. DeWitt DE, Hirsch IB. Outpatient insulin
therapy in type 1 and type 2 diabetes mellitus:
scientific review. JAMA 2003;289:2254–2264

9. Bode BW, McGill JB, Lorber DL, Gross JL, Chang
PC; Affinity 1 Study Group. Inhaled technosphere
insulin compared with injected prandial insulin
in type 1 diabetes: a randomized 24-week trial.
Diabetes Care 2015;38:2266–2273

10. Russell-Jones D, Bode BW, De Block C, et al.
Fast-acting insulin aspart improves glycemic control
in basal-bolus treatment for type 1 diabetes:
results of a 26-week multicenter, active-controlled,
treat-to-target, randomized, parallel-group trial
(onset 1). Diabetes Care 2017;40:943–950

11. Klaff L, Cao D, Dellva MA, et al. Ultra rapid
lispro improves postprandial glucose control
compared with lispro in patients with type 1
diabetes: Results from the 26-week PRONTO-T1D
study. Diabetes ObesMetab 2020;22:1799–1807

12. Blevins T, Zhang Q, Frias JP, Jinnouchi H;
PRONTO-T2D Investigators. Randomized doubleblind
clinical trial comparing ultra rapid lispro
with lispro in a basal-bolus regimen in patients
with type 2 diabetes: PRONTO-T2D. Diabetes Care
2020;43:2991–2998

13. Lane W, Bailey TS, Gerety G, et al.; Group
Information; SWITCH 1. Effect of insulin degludec
vs insulin glargine U100 on hypoglycemia in
patients with type 1 diabetes: the SWITCH 1
randomized clinical trial. JAMA 2017;318:33–44

14. Home PD, Bergenstal RM, Bolli GB, et al.
New insulin glargine 300 units/mL versus glargine
100 units/mL in people with type 1 diabetes: a
randomized, phase 3a, open-label clinical trial
(EDITION 4). Diabetes Care 2015;38:2217–2225

15. Yeh HC, Brown TT, Maruthur N, et al.
Comparative effectiveness and safety of methods
of insulin delivery and glucose monitoring for
diabetes mellitus: a systematic review and metaanalysis.
Ann InternMed 2012;157:336–347

16. Pickup JC. The evidence base for diabetes
technology: appropriate and inappropriate metaanalysis.
J Diabetes Sci Technol 2013;7:1567–1574

17. Bergenstal RM, Klonoff DC, Garg SK, et al.;
ASPIRE In-Home Study Group. Threshold-based
insulin-pump interruption for reduction of hypoglycemia.
N Engl JMed 2013;369:224–232

18. Buckingham BA, Raghinaru D, Cameron F,
et al.; In Home Closed Loop Study Group.
Predictive low-glucose insulin suspension reduces
duration of nocturnal hypoglycemia in children
without increasing ketosis. Diabetes Care 2015;
38:1197–1204

19. Bergenstal RM, Garg S,Weinzimer SA, et al.
Safety of a hybrid closed-loop insulin delivery
system in patients with type 1 diabetes. JAMA
2016;316:1407–1408

20. Garg SK, Weinzimer SA, Tamborlane WV,
et al. Glucose outcomes with the in-home use of
a hybrid closed-loop insulin delivery system in
adolescents and adults with type 1 diabetes.
Diabetes Technol Ther 2017;19:155–163

21. Tauschmann M, Thabit H, Bally L, et al.;
APCam11 Consortium. Closed-loop insulin delivery
in suboptimally controlled type 1 diabetes: a
S154 Pharmacologic Approaches to Glycemic Treatment Diabetes Care Volume 46, Supplement 1, January 2023
Downloaded from http://diabetesjournals.org/care/article-pdf/46/Supplement_1/S140/693669/dc23s009.pdf by guest on 05 October 2023
multicentre, 12-week randomised trial. Lancet
2018;392:1321–1329

22. Brown SA, Kovatchev BP, Raghinaru D, et al.;
iDCL Trial Research Group. Six-month randomized,
multicenter trial of closed-loop control in type 1
diabetes. N Engl JMed 2019;381:1707–1717

23. Peters AL, Laffel L (Eds.). American Diabetes
Association/JDRF Type 1 Diabetes Sourcebook.
Alexandria, VA, American Diabetes Association,
2013

24. Chiang JL, Kirkman MS, Laffel LMB; Type 1
Diabetes Sourcebook Authors. Type 1 diabetes
through the life span: a position statement of the
American Diabetes Association. Diabetes Care
2014;37:2034–2054

25. Bell KJ, Barclay AW, Petocz P, Colagiuri S,
Brand-Miller JC. Efficacy of carbohydrate counting
in type 1 diabetes: a systematic review and metaanalysis.
Lancet Diabetes Endocrinol 2014;2:133–
140

26. Vaz EC, Porf ırio GJM, Nunes HRC, Nunes-Nogueira
VDS. Effectiveness and safety of carbohydrate
counting in themanagement of adult patients with
type 1 diabetesmellitus: a systematic review and
meta-analysis. Arch Endocrinol Metab 2018;62:
337–345

27. Bell KJ, Smart CE, Steil GM, Brand-Miller JC,
King B, Wolpert HA. Impact of fat, protein, and
glycemic index on postprandial glucose control in
type 1 diabetes: implications for intensive diabetes
management in the continuous glucosemonitoring
era. Diabetes Care 2015;38:1008–1015

28. FridAH, Kreugel G,Grassi G, et al.Newinsulin
delivery recommendations. Mayo Clin Proc 2016;
91:1231–1255

29. Bergenstal RM, Strock ES, Peremislov D,
GibneyMA, Parvu V, Hirsch LJ. Safety and efficacy
of insulin therapy delivered via a 4mm pen
needle in obese patients with diabetes. Mayo
Clin Proc 2015;90:329–338

30. Whitehouse F, Kruger DF, Fineman M, et al.
A randomized study and open-label extension
evaluating the long-term efficacy of pramlintide
as an adjunct to insulin therapy in type 1 diabetes.
Diabetes Care 2002;25:724–730

31. Ratner RE, Want LL, Fineman MS, et al.
Adjunctive therapy with the amylin analogue
pramlintide leads to a combined improvement in
glycemic and weight control in insulin-treated
subjects with type 2 diabetes. Diabetes Technol
Ther 2002;4:51–61

32. Hollander PA, Levy P, Fineman MS, et al.
Pramlintide as an adjunct to insulin therapy
improves long-termglycemic and weight control in
patients with type 2 diabetes: a 1-year randomized
controlled trial. Diabetes Care 2003;26:784–790

33. Ratner RE, Dickey R, Fineman M, et al. Amylin
replacement with pramlintide as an adjunct to
insulin therapy improves long-term glycaemic and
weight control in type 1 diabetes mellitus: a 1-year,
randomized controlled trial. Diabet Med 2004;
21:1204–1212

34. Meng H, Zhang A, Liang Y, Hao J, Zhang X, Lu
J. Effect of metformin on glycaemic control in
patients with type 1 diabetes: a meta-analysis of
randomized controlled trials. DiabetesMetab Res
Rev 2018;34:e2983

35. Petrie JR, Chaturvedi N, Ford I, et al.; REMOVAL
Study Group. Cardiovascular and metabolic effects
of metformin in patients with type 1 diabetes
(REMOVAL): a double-blind, randomised, placebocontrolled
trial. Lancet Diabetes Endocrinol
2017;5:597–609

36. Mathieu C, Zinman B, Hemmingsson JU,
et al.; ADJUNCT ONE Investigators. Efficacy and
safety of liraglutide added to insulin treatment in
type 1 diabetes: the ADJUNCT ONE treat-to-target
randomized trial. Diabetes Care 2016;39:1702–
1710

37. Ahr en B, Hirsch IB, Pieber TR, et al.; ADJUNCT
TWO Investigators. Efficacy and safety of liraglutide
added to capped insulin treatment in subjects with
type 1 diabetes: the ADJUNCT TWO randomized
trial. Diabetes Care 2016;39:1693–1701

38. Dandona P,Mathieu C, PhillipM, et al.; DEPICT-1
Investigators. Efficacy and safety of dapagliflozin in
patientswith inadequately controlled type 1 diabetes
(DEPICT-1): 24 week results from a multicentre,
double-blind, phase 3, randomised controlled
trial. Lancet Diabetes Endocrinol 2017;5:864–876

39. Rosenstock J, Marquard J, Laffel LM, et al.
Empagliflozin as adjunctive to insulin therapy in
type 1 diabetes: the EASE trials. Diabetes Care
2018;41:2560–2569

40. Snaith JR, Holmes-Walker DJ, Greenfield JR.
Reducing type 1 diabetes mortality: role for
adjunctive therapies? Trends Endocrinol Metab
2020;31:150–164

41. Danne T, Garg S, Peters AL, et al. International
consensus on risk management of diabetic
ketoacidosis in patients with type 1 diabetes
treated with sodium-glucose cotransporter (SGLT)
inhibitors. Diabetes Care 2019;42:1147–1154

42. Dean PG, Kukla A, Stegall MD, Kudva YC.
Pancreas transplantation. BMJ 2017;357:j1321.
Accessed 18 October 2022. Available from
https://www.bmj.com/content/357/bmj.j1321

43. Davies MJ, D’Alessio DA, Fradkin J, et al.
Management of hyperglycemia in type 2 diabetes,
2018. A consensus report by the American Diabetes
Association (ADA) and the European Association for
the Study of Diabetes (EASD). Diabetes Care 2018;
41:2669–2701

44. Buse JB, Wexler DJ, Tsapas A, et al. 2019
Update to: management of hyperglycemia in
type 2 diabetes, 2018. A consensus report by the
American Diabetes Association (ADA) and the
European Association for the Study of Diabetes
(EASD). Diabetes Care 2020;43:487–493

45. Davies MJ, Aroda VR, Collins BS, et al.
Management of hyperglycemia in type 2 diabetes,
2022. A consensus report by the American Diabetes
Association (ADA) and the European Association for
the Study of Diabetes (EASD). Diabetes Care 2022;
45:2753–2786

46. Lingvay I, Sumithran P, Cohen RV, le Roux
CW. Obesity management as a primary treatment
goal for type 2 diabetes: time to reframe the
conversation. Lancet 2022;399:394–405

47. Holman RR, Paul SK, Bethel MA, Matthews
DR, Neil HAW. 10-year follow-up of intensive
glucose control in type 2 diabetes. N Engl J Med
2008;359:1577–1589

48. Maruthur NM, Tseng E, Hutfless S, et al.
Diabetes medications as monotherapy or metforminbased
combination therapy for type 2 diabetes: a
systematic review and meta-analysis. Ann Intern
Med 2016;164:740–751

49. U.S. Food and Drug Administration. FDA Drug
Safety Communication: FDA revises warnings
regarding use of the diabetes medicine metformin
in certain patients with reduced kidney function.
Accessed 18 October 2022. Available from https://
www.fda.gov/drugs/drug-safety-and-availability/fdadrug-
safety-communication-fda-revises-warningsregarding-
use-diabetes-medicine-metformin-certain

50. Out M, Kooy A, Lehert P, Schalkwijk CA,
Stehouwer CDA. Long-term treatment with
metformin in type 2 diabetes and methylmalonic
acid: post hoc analysis of a randomized controlled
4.3-year trial. J Diabetes Complications 2018;32:
171–178

51. Aroda VR, Edelstein SL, Goldberg RB, et al.;
Diabetes Prevention Program Research Group.
Long-termmetformin use and vitamin B12 deficiency
in the Diabetes Prevention ProgramOutcomes Study.
J Clin EndocrinolMetab 2016;101:1754–1761

52. Henry RR, Murray AV, Marmolejo MH,
Hennicken D, Ptaszynska A, List JF. Dapagliflozin,
metformin XR, or both: initial pharmacotherapy
for type 2 diabetes, a randomised controlled trial.
Int J Clin Pract 2012;66:446–456

53. Babu A, Mehta A, Guerrero P, et al. Safe and
simple emergency department discharge therapy
for patients with type 2 diabetes mellitus and
severe hyperglycemia. Endocr Pract 2009;15:
696–704

54. Cahn A, Cefalu WT. Clinical considerations
for use of initial combination therapy in type 2
diabetes. Diabetes Care 2016;39(Suppl. 2):S137–
S145

55. Abdul-Ghani MA, Puckett C, Triplitt C, et al.
Initial combination therapy with metformin,
pioglitazone and exenatide is more effective than
sequential add-on therapy in subjects with newonset
diabetes. Results from the Efficacy and
Durability of Initial Combination Therapy for
Type 2 Diabetes (EDICT): a randomized trial.
Diabetes Obes Metab 2015;17:268–275

56. Phung OJ, Sobieraj DM, Engel SS, Rajpathak
SN. Early combination therapy for the treatment
of type 2 diabetesmellitus: systematic review and
meta-analysis. Diabetes Obes Metab 2014;16:
410–417

57. Aroda VR, Gonz alez-Galvez G, Grøn R, et al.
Durability of insulin degludec plus liraglutide versus
insulin glargine U100 as initial injectable therapy in
type 2 diabetes (DUAL VIII): a multicentre, openlabel,
phase 3b, randomised controlled trial. Lancet
Diabetes Endocrinol 2019;7:596–605

58. Matthews DR, Pald anius PM, Proot P, Chiang
Y, Stumvoll M; VERIFY study group. Glycaemic
durability of an early combination therapy with
vildagliptin and metformin versus sequential
metforminmonotherapy in newly diagnosed type 2
diabetes (VERIFY): a 5-year, multicentre, randomised,
double-blind trial. Lancet 2019;394:1519–1529

59. Bennett WL, Maruthur NM, Singh S, et al.
Comparative effectiveness and safety of medications
for type 2 diabetes: an update including new drugs
and 2-drug combinations. Ann Intern Med 2011;
154:602–613

60. Maloney A, Rosenstock J, Fonseca V. Amodelbased
meta-analysis of 24 antihyperglycemic drugs
for type 2 diabetes: comparison of treatment
effects at therapeutic doses. Clin Pharmacol Ther
2019;105:1213–1223

61. Vijan S, Sussman JB, Yudkin JS, Hayward RA.
Effect of patients’ risks and preferences on health
gains with plasma glucose level lowering in type 2
diabetes mellitus. JAMA Intern Med 2014;174:
1227–1234

62. Tsapas A, Avgerinos I, Karagiannis T, et al.
Comparative effectiveness of glucose-lowering
drugs for type 2 diabetes: a systematic review
diabetesjournals.org/care Pharmacologic Approaches to Glycemic Treatment S155
Downloaded from http://diabetesjournals.org/care/article-pdf/46/Supplement_1/S140/693669/dc23s009.pdf by guest on 05 October 2023
and network meta-analysis. Ann Intern Med
2020;173:278–286

63. Pratley R, Amod A, Hoff ST, et al.; PIONEER 4
investigators. Oral semaglutide versus subcutaneous
liraglutide and placebo in type 2 diabetes (PIONEER
4): a randomized, double-blind, phase 3a trial. Lancet
2019;394:39–50

64. Singh S, Wright EE Jr, Kwan AYM, et al.
Glucagon-like peptide-1 receptor agonists compared
with basal insulins for the treatment of type 2
diabetes mellitus: a systematic review and metaanalysis.
Diabetes ObesMetab 2017;19:228–238

65. Levin PA, Nguyen H, Wittbrodt ET, Kim SC.
Glucagon-like peptide-1 receptor agonists: a
systematic review of comparative effectiveness
research. Diabetes Metab Syndr Obes 2017;10:
123–139

66. Abd El Aziz MS, Kahle M, Meier JJ, Nauck
MA. A meta-analysis comparing clinical effects
of short- or long-acting GLP-1 receptor agonists
versus insulin treatment from head-to-head
studies in type 2 diabetic patients. Diabetes
ObesMetab 2017;19:216–227

67. Giorgino F, BenroubiM, Sun JH, Zimmermann
AG, Pechtner V. Efficacy and safety of once-weekly
dulaglutide versus insulin glargine in patients with
type 2 diabetes on metformin and glimepiride
(AWARD-2). Diabetes Care 2015;38:2241–2249

68. Aroda VR, Bain SC, Cariou B, et al. Efficacy and
safety of once-weekly semaglutide versus oncedaily
insulin glargine as add-on to metformin (with
or without sulfonylureas) in insulin-naive patients
with type 2 diabetes (SUSTAIN 4): a randomised,
open-label, parallel-group,multicentre, multinational,
phase 3a trial. Lancet Diabetes Endocrinol 2017;
5:355–366

69. Davies M, Heller S, Sreenan S, et al. Onceweekly
exenatide versus once- or twice-daily
insulin detemir: randomized, open-label, clinical
trial of efficacy and safety in patients with type 2
diabetes treated with metformin alone or in
combination with sulfonylureas. Diabetes Care
2013;36:1368–1376

70. DiamantM,Van Gaal L, Stranks S, et al. Once
weekly exenatide compared with insulin glargine
titrated to target in patients with type 2 diabetes
(DURATION-3): an open-label randomised trial.
Lancet 2010;375:2234–2243

71. RiddleMC, HermanWH. The cost of diabetes
care-an elephant in the room. Diabetes Care
2018;41:929–932

72. IBM. Micromedex Red Book. Accessed
9 November 2022. Available from https://www.
ibm.com/products/micromedex-red-book

73. Data.Medicaid.gov. NADAC (National Average
Drug Acquisition Cost). Accessed 23 October 2022.
Available from https://data.medicaid.gov/dataset/
dfa2ab14-06c2-457a-9e36-5cb6d80f8d93

74. Kang H, Lobo JM, Kim S, Sohn MW. Costrelated
medication non-adherence among U.S.
adults with diabetes. Diabetes Res Clin Pract
2018;143:24–33

75. Patel MR, Piette JD, Resnicow K, Kowalski-
Dobson T, HeislerM. Social determinants of health,
cost-related nonadherence, and cost-reducing behaviors
among adults with diabetes: findings from the
National Health interview survey. Med Care
2016;54:796–803

76. Gerstein HC, Sattar N, Rosenstock J, et al.;
AMPLITUDE-O Trial Investigators. Cardiovascular
and renal outcomes with efpeglenatide in type 2
diabetes. N Engl JMed 2021;385:896–907

77. Blonde L, Merilainen M, Karwe V; TITRATE
Study Group. Patient-directed titration for achieving
glycaemic goals using a once-daily basal insulin
analogue: an assessment of two different fasting
plasma glucose targets–the TITRATE study. Diabetes
Obes Metab 2009;11:623–631

78. Porcellati F, Lucidi P, Cioli P, et al. Pharmacokinetics
and pharmacodynamics of insulin
glargine given in the evening as compared with
in the morning in type 2 diabetes. Diabetes Care
2015;38:503–512

79. Wang Z, HedringtonMS, Gogitidze Joy N, et al.
Dose-response effects of insulin glargine in type 2
diabetes. Diabetes Care 2010;33:1555–1560

80. Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett
H. Efficacy and safety of insulin analogues for the
management of diabetes mellitus: a meta-analysis.
CMAJ 2009;180:385–397

81. Horvath K, Jeitler K, Berghold A, et al. Longacting
insulin analogues versus NPH insulin (human
isophane insulin) for type 2 diabetes mellitus.
Cochrane Database Syst Rev 2007 2:CD005613

82. Monami M, Marchionni N, Mannucci E. Longacting
insulin analogues versus NPH human insulin
in type 2 diabetes: a meta-analysis. Diabetes Res
Clin Pract 2008;81:184–189

83. Owens DR, Traylor L, Mullins P, Landgraf
W. Patient-level meta-analysis of efficacy and
hypoglycaemia in people with type 2 diabetes
initiating insulin glargine 100U/mL or neutral
protamine Hagedorn insulin analysed according to
concomitant oral antidiabetes therapy. Diabetes
Res Clin Pract 2017;124(Suppl. C):57–65

84. Riddle MC, Rosenstock J; Insulin Glargine
4002 Study Investigators. The treat-to-target trial:
randomized addition of glargine or human NPH
insulin to oral therapy of type 2 diabetic patients.
Diabetes Care 2003;26:3080–3086

85. Hermansen K, Davies M, Derezinski T,
Martinez Ravn G, Clauson P, Home P. A 26-week,
randomized, parallel, treat-to-target trial comparing
insulin detemir with NPH insulin as add-on therapy
to oral glucose-lowering drugs in insulin-naive
people with type 2 diabetes. Diabetes Care 2006;
29:1269–1274

86. Yki-J€arvinen H, Kauppinen-M€akelin R, Tiikkainen
M, et al. Insulin glargine or NPH combined with
metformin in type 2 diabetes: the LANMET study.
Diabetologia 2006;49:442–451

87. Bolli GB, RiddleMC, Bergenstal RM, et al.; on
behalf of the EDITION 3 Study Investigators. New
insulin glargine 300 U/ml compared with glargine
100 U/ml in insulin-naïve people with type 2
diabetes on oral glucose-lowering drugs: a
randomized controlled trial (EDITION 3). Diabetes
ObesMetab 2015;17:386–394

88. Terauchi Y, Koyama M, Cheng X, et al. New
insulin glargine 300 U/ml versus glargine 100 U/ml
in Japanese people with type 2 diabetes using
basal insulin and oral antihyperglycaemic drugs:
glucose control and hypoglycaemia in a randomized
controlled trial (EDITION JP 2). Diabetes Obes
Metab 2016;18:366–374

89. Yki-J€arvinen H, Bergenstal RM, Bolli GB, et al.
Glycaemic control and hypoglycaemia with new
insulin glargine 300 U/ml versus insulin glargine
100 U/ml in people with type 2 diabetes using
basal insulin and oral antihyperglycaemic drugs:
the EDITION 2 randomized 12-month trial including
6-month extension. Diabetes Obes Metab 2015;
17:1142–1149

90. Marso SP, McGuire DK, Zinman B, et al.;
DEVOTE Study Group. Efficacy and safety of
degludec versus glargine in type 2 diabetes. N
Engl JMed 2017;377:723–732

91. RodbardHW, Cariou B, Zinman B, et al.; BEGIN
Once Long Trial Investigators. Comparison of insulin
degludec with insulin glargine in insulin-naive
subjects with type 2 diabetes: a 2-year randomized,
treat-to-target trial. Diabet Med 2013;30:1298–
1304

92. Wysham C, Bhargava A, Chaykin L, et al. Effect
of insulin degludec vs insulin glargine u100 on
hypoglycemia in patients with type 2 diabetes: the
SWITCH 2 randomized clinical trial. JAMA 2017;
318:45–56

93. Zinman B, Philis-Tsimikas A, Cariou B, et al.;
NN1250-3579 (BEGIN Once Long) Trial Investigators.
Insulin degludec versus insulin glargine in insulinnaive
patients with type 2 diabetes: a 1-year,
randomized, treat-to-target trial (BEGIN Once Long).
Diabetes Care 2012;35:2464–2471

94. Cowart K. Overbasalization: addressing hesitancy
in treatment intensification beyond basal insulin.
Clin Diabetes 2020;38:304–310

95. Cefalu WT, Dawes DE, Gavlak G, et al.;
Insulin Access and Affordability Working Group.
Conclusions and recommendations. Diabetes Care
2018;41:1299–1311

96. Lipska KJ, Parker MM, Moffet HH, Huang ES,
Karter AJ. Association of initiation of basal insulin
analogs vs neutral protamine hagedorn insulin
with hypoglycemia-related emergency department
visits or hospital admissions and with glycemic
control in patients with type 2 diabetes. JAMA
2018;320:53–62

97. McCall AL. Insulin therapy and hypoglycemia.
Endocrinol Metab Clin North Am2012;41:57–87

98. Mannucci E, Monami M, Marchionni N.
Short-acting insulin analogues vs. regular human
insulin in type 2 diabetes: a meta-analysis.
Diabetes Obes Metab 2009;11:53–59

99. Heller S, Bode B, Kozlovski P, Svendsen AL.
Meta-analysis of insulin aspart versus regular
human insulin used in a basal-bolus regimen for
the treatment of diabetes mellitus. J Diabetes
2013;5:482–491

100. Wysham C, Hood RC,Warren ML, Wang T,
Morwick TM, Jackson JA. Effect of total daily
dose on efficacy, dosing, and safety of 2 dose
titration regimens of human regular U500 insulin
in severely insulin-resistant patients with type 2
diabetes. Endocr Pract 2016;22:653–665

101. Riddle MC, Yki-J€arvinen H, Bolli GB, et al.
One-year sustained glycaemic control and less
hypoglycaemia with new insulin glargine 300 U/ml
compared with 100 U/ml in people with type 2
diabetes using basal plus meal-time insulin: the
EDITION 1 12-month randomized trial, including
6-month extension. Diabetes Obes Metab 2015;
17:835–842

102. Yki-J€arvinenH, Bergenstal R, ZiemenM, et al.;
EDITION 2 Study Investigators. New insulin glargine
300 units/mL versus glargine 100 units/mL in
people with type 2 diabetes using oral agents and
basal insulin: glucose control and hypoglycemia in a
6-month randomized controlled trial (EDITION 2).
Diabetes Care 2014;37:3235–3243

103. Akturk HK, Snell-Bergeon JK, Rewers A,
et al. Improved postprandial glucose with inhaled
technosphere insulin compared with insulin aspart
in patients with type 1 diabetes on multiple daily
S156 Pharmacologic Approaches to Glycemic Treatment Diabetes Care Volume 46, Supplement 1, January 2023
Downloaded from http://diabetesjournals.org/care/article-pdf/46/Supplement_1/S140/693669/dc23s009.pdf by guest on 05 October 2023
injections: the STAT study. Diabetes Technol Ther
2018;20:639–647

104. Hoogwerf BJ, Pantalone KM, BasinaM, Jones
MC, Grant M, Kendall DM. Results of a 24-week
trial of technosphere insulin versus insulin aspart in
type 2 diabetes. Endocr Pract 2021;27:38–43

105. Grant M, Heise T, Baughman R. Comparison
of pharmacokinetics and pharmacodynamics of
inhaled technosphere insulin and subcutaneous
insulin lispro in the treatment of type 1 diabetes
mellitus. Clin Pharmacokinet 2022;61:413–422

106. Diamant M, Nauck MA, Shaginian R, et al.;
4B Study Group. Glucagon-like peptide 1 receptor
agonist or bolus insulin with optimized basal
insulin in type 2 diabetes. Diabetes Care 2014;
37:2763–2773

107. Eng C, Kramer CK, Zinman B, Retnakaran R.
Glucagon-like peptide-1 receptor agonist and basal
insulin combination treatment for the management
of type 2 diabetes: a systematic review and metaanalysis.
Lancet 2014;384:2228–2234

108. MaiorinoMI, Chiodini P, Bellastella G, Capuano
A, Esposito K, Giugliano D. Insulin and glucagon-like
peptide 1 receptor agonist combination therapy in
type 2 diabetes: a systematic review and metaanalysis
of randomized controlled trials. Diabetes
Care 2017;40:614–624

109. Aroda VR, Rosenstock J, Wysham C, et al.;
LixiLan-L Trial Investigators. Efficacy and safety of
LixiLan, a titratable fixed-ratio combination of
insulin glargine plus lixisenatide in type 2 diabetes
inadequately controlled on basal insulin andmetformin:
the LixiLan-L randomized trial. Diabetes Care 2016;
39:1972–1980

110. Lingvay I, P erezManghi F, Garc ıa-Hern andez
P, et al.; DUAL V Investigators. Effect of insulin
glargine up-titration vs insulin degludec/liraglutide
on glycated hemoglobin levels in patients with
uncontrolled type 2 diabetes: the DUAL V randomized
clinical trial. JAMA 2016;315:898–907

111. Dahl D, Onishi Y, Norwood P, et al. Effect
of subcutaneous tirzepatide vs placebo added
to titrated insulin glargine on glycemic control in
patients with type 2 diabetes: the SURPASS-5
randomized clinical trial. JAMA 2022;327:534–
545

112. Taybani Z, B otyik B, Katk o M, Gyimesi A,
V arkonyi T. Simplifying complex insulin regimens
while preserving good glycemic control in type 2
diabetes. Diabetes Ther 2019;10:1869–1878

113. Rodbard HW, Visco VE, Andersen H, Hiort LC,
Shu DHW. Treatment intensification with
stepwise addition of prandial insulin aspart
boluses compared with full basal-bolus therapy
(FullSTEP Study): a randomised, treat-to-target
clinical trial. Lancet Diabetes Endocrinol 2014;2:
30–37

114. Tsapas A, Karagiannis T, Kakotrichi P, et al.
Comparative efficacy of glucose-lowering medications
on body weight and blood pressure in patients with
type 2 diabetes: A systematic review and network
meta-analysis. Diabetes Obes Metab 2021;23:
2116–2124